© Reuters.
MONTREAL – Theratechnologies (NASDAQ:) Inc. (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company, announced today the immediate resignation of Mr. Alain Trudeau from its Board of Directors and Audit Committee. Mr. Trudeau had been part of the company since October 2020, contributing to its governance and strategic oversight.
During his tenure, Trudeau served as Chair of the Audit Committee and was a member of the Compensation Committee until March 2023. Dawn Svoronos, Chair of the Board, expressed gratitude for his service, particularly noting his role in completing the annual review for the 2023 fiscal year.
Following the resignation, the Board has appointed Frank Holler as the new Chair of the Audit Committee. In line with securities regulation compliance, plans are in place to appoint a new independent director to the committee. The Board will also evaluate the possibility of appointing an additional member to fill the vacancy before the next annual shareholders’ meeting.
Theratechnologies is known for its focus on developing innovative therapies that address unmet medical needs. The company has stated that the Board’s decisions on these matters will be made with careful consideration of the best interests of the company and its shareholders.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.